VirtualScopics (VirtualScopics) Net Income From Continuing Operations : $-1.04 Mil (TTM As of Dec. 2015)

VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.